Tricida Inc (TCDA) Shares Sold by Citigroup Inc.
Citigroup Inc. trimmed its holdings in shares of Tricida Inc (NASDAQ:TCDA) by 26.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 2,411 shares of the company’s stock after selling 851 shares during the period. Citigroup Inc.’s holdings in Tricida were worth $57,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in the company. Legal & General Group Plc acquired a new position in shares of Tricida during the 3rd quarter worth approximately $54,000. TD Asset Management Inc. increased its position in shares of Tricida by 17.7% during the fourth quarter. TD Asset Management Inc. now owns 23,297 shares of the company’s stock worth $549,000 after purchasing an additional 3,500 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Tricida by 2.1% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 205,409 shares of the company’s stock worth $4,844,000 after purchasing an additional 4,239 shares in the last quarter. Wells Fargo & Company MN purchased a new stake in shares of Tricida during the third quarter worth approximately $170,000. Finally, United Services Automobile Association increased its position in shares of Tricida by 30.8% during the third quarter. United Services Automobile Association now owns 24,848 shares of the company’s stock worth $759,000 after purchasing an additional 5,848 shares in the last quarter. 69.83% of the stock is owned by institutional investors and hedge funds.
Shares of TCDA opened at $34.58 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 16.50 and a quick ratio of 16.51. Tricida Inc has a one year low of $19.43 and a one year high of $40.83. The company has a market cap of $1.56 billion and a P/E ratio of -7.45.
Several brokerages recently commented on TCDA. Zacks Investment Research upgraded Tricida from a “hold” rating to a “buy” rating and set a $42.00 price target for the company in a research report on Saturday, March 30th. Empire boosted their price target on Tricida from $37.00 to $58.00 in a research report on Monday, April 1st.
In other Tricida news, Director Klaus R. Dr Veitinger sold 6,000 shares of the company’s stock in a transaction on Friday, January 25th. The stock was sold at an average price of $20.86, for a total value of $125,160.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Claire Lockey sold 13,494 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $25.01, for a total value of $337,484.94. The disclosure for this sale can be found here. Insiders have sold 151,794 shares of company stock valued at $4,407,688 over the last quarter.
TRADEMARK VIOLATION NOTICE: This story was published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/tricida-inc-tcda-shares-sold-by-citigroup-inc/2952188.html.
Tricida Company Profile
Tricida, Inc, a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). It has completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis.
Read More: How to execute a trade ex-dividend strategy?
Want to see what other hedge funds are holding TCDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tricida Inc (NASDAQ:TCDA).
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.